WO2012089207A3 - Pharmazeutische zusammensetzung enthaltend l-dna - Google Patents

Pharmazeutische zusammensetzung enthaltend l-dna Download PDF

Info

Publication number
WO2012089207A3
WO2012089207A3 PCT/DE2012/000008 DE2012000008W WO2012089207A3 WO 2012089207 A3 WO2012089207 A3 WO 2012089207A3 DE 2012000008 W DE2012000008 W DE 2012000008W WO 2012089207 A3 WO2012089207 A3 WO 2012089207A3
Authority
WO
WIPO (PCT)
Prior art keywords
dna
rna
pharmaceutical composition
composition containing
cleave
Prior art date
Application number
PCT/DE2012/000008
Other languages
English (en)
French (fr)
Other versions
WO2012089207A2 (de
Inventor
Volker A. Erdmann
Original Assignee
Erdmann Volker A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Erdmann Volker A filed Critical Erdmann Volker A
Priority to KR1020137020401A priority Critical patent/KR20140043052A/ko
Priority to RU2013135647/10A priority patent/RU2013135647A/ru
Priority to US13/977,088 priority patent/US20130345290A1/en
Priority to JP2013546589A priority patent/JP2014504589A/ja
Priority to CA2850863A priority patent/CA2850863A1/en
Priority to AU2012203994A priority patent/AU2012203994A1/en
Priority to CN201280011039.2A priority patent/CN103492571A/zh
Priority to EP12716194.1A priority patent/EP2668275A2/de
Priority to MX2013007543A priority patent/MX2013007543A/es
Priority to BR112013017001A priority patent/BR112013017001A2/pt
Publication of WO2012089207A2 publication Critical patent/WO2012089207A2/de
Publication of WO2012089207A3 publication Critical patent/WO2012089207A3/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/127—DNAzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft die Verwendung einer L-DNA, welche zur Bindung an eine L-RNA befähigt ist, insbesondere in einer antisense Reaktion, und optional zur Spaltung der L-RNA im Bereich einer Targetsequenz der L-RNA befähigt ist, zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von unerwünschten physiologischen Nebenreaktionen aufgrund der Gabe eines therapeutischen Moleküls enthaltend die L-RNA. Mit der L-DNA kann aber auch alternativ eine endogene Target RNA oder DNA gespalten werden.
PCT/DE2012/000008 2010-12-31 2012-01-02 Pharmazeutische zusammensetzung enthaltend l-dna WO2012089207A2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
KR1020137020401A KR20140043052A (ko) 2010-12-31 2012-01-02 L-dna를 함유하는 약제학적 조성물
RU2013135647/10A RU2013135647A (ru) 2010-12-31 2012-01-02 Фармацевтическая композиция, содержащая l-днк
US13/977,088 US20130345290A1 (en) 2010-12-31 2012-01-02 Pharmaceutical composition containing l-dna
JP2013546589A JP2014504589A (ja) 2010-12-31 2012-01-02 Ｌ−ｄｎａを含む医薬組成物
CA2850863A CA2850863A1 (en) 2010-12-31 2012-01-02 Pharmaceutical composition comprising l-dna
AU2012203994A AU2012203994A1 (en) 2010-12-31 2012-01-02 Pharmaceutical composition containing L-DNA
CN201280011039.2A CN103492571A (zh) 2010-12-31 2012-01-02 含l-dna的药物组合物
EP12716194.1A EP2668275A2 (de) 2010-12-31 2012-01-02 Pharmazeutische zusammensetzung enthaltend l-dna
MX2013007543A MX2013007543A (es) 2010-12-31 2012-01-02 Composicion farmaceutica conteniendo l-adn.
BR112013017001A BR112013017001A2 (pt) 2010-12-31 2012-01-02 composição farmacêutica contendo l-dna

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102010056610.1 2010-12-31
DE102010056610A DE102010056610A1 (de) 2010-12-31 2010-12-31 Pharmazeutische Zusammensetzung enthaltend L-DNA

Publications (2)

Publication Number Publication Date
WO2012089207A2 WO2012089207A2 (de) 2012-07-05
WO2012089207A3 true WO2012089207A3 (de) 2012-10-04

Family

ID=45999500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2012/000008 WO2012089207A2 (de) 2010-12-31 2012-01-02 Pharmazeutische zusammensetzung enthaltend l-dna

Country Status (12)

Country Link
US (1) US20130345290A1 (de)
EP (1) EP2668275A2 (de)
JP (1) JP2014504589A (de)
KR (1) KR20140043052A (de)
CN (1) CN103492571A (de)
AU (1) AU2012203994A1 (de)
BR (1) BR112013017001A2 (de)
CA (1) CA2850863A1 (de)
DE (1) DE102010056610A1 (de)
MX (1) MX2013007543A (de)
RU (1) RU2013135647A (de)
WO (1) WO2012089207A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
US9983565B2 (en) * 2015-03-27 2018-05-29 Intel Corporation Technologies for bio-chemically controlling operation of a machine
CN105274196A (zh) * 2015-04-01 2016-01-27 湖南大学 一种基于l型脱氧核酶生物体系中金属离子的检测试剂盒、检测方法和应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008856A2 (de) * 1996-08-30 1998-03-05 Fuerste Jens Peter Spiegelselektion und spiegelevolution von nucleinsäuren
WO1999036430A1 (de) * 1998-01-13 1999-07-22 BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH Oligoliganden mit bindungsvermögen
DE10020275A1 (de) * 2000-04-25 2001-10-31 Manfred Schneider Enantiomere Bausteine der 2-Deoxy-L-Ribose und 2-Deoxy-D-Ribose, Verfahren zu ihrer Herstellung sowie Verwendung zur Synthese von natürlichen und nicht natürliche L- und D-Nucleinsäuren, L- und D- konfigurierten Oligonucleotiden, L- und D-konfigurierter DNA und davon abgeleiteten pharmazeutischen Wirkstoffen
WO2002100442A2 (en) * 2001-06-10 2002-12-19 Noxxon Pharma Ag Use of l-polynucleotides and derivatives thereof for in vivo imaging
WO2004030660A2 (en) * 2002-10-02 2004-04-15 The University Of British Columbia Compositions for treatment of prostate and other cancers
WO2008087641A2 (en) * 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
WO2010088899A2 (de) * 2009-02-06 2010-08-12 Freie Universität Berlin Pharmazeutische zusammensetzung zur behandlung von nebenwirkungen durch gabe von spiegelmeren

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219422A1 (en) * 2001-11-15 2003-11-27 Noxxon Pharma Ag Allosteric ribozymes and uses thereof
DE10346487A1 (de) * 2003-10-02 2005-05-12 Transmit Technologietransfer Verfahren zur Herstellung eines Zell- und/oder Gewebe- und/oder Krankheitsphasen-spezifischen Arzneimittels
CA2607185A1 (en) * 2005-05-04 2006-11-09 Noxxon Pharma Ag Intracellular active agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008856A2 (de) * 1996-08-30 1998-03-05 Fuerste Jens Peter Spiegelselektion und spiegelevolution von nucleinsäuren
WO1999036430A1 (de) * 1998-01-13 1999-07-22 BioteCon Gesellschaft für Biotechnologische Entwicklung und Consulting mbH Oligoliganden mit bindungsvermögen
DE10020275A1 (de) * 2000-04-25 2001-10-31 Manfred Schneider Enantiomere Bausteine der 2-Deoxy-L-Ribose und 2-Deoxy-D-Ribose, Verfahren zu ihrer Herstellung sowie Verwendung zur Synthese von natürlichen und nicht natürliche L- und D-Nucleinsäuren, L- und D- konfigurierten Oligonucleotiden, L- und D-konfigurierter DNA und davon abgeleiteten pharmazeutischen Wirkstoffen
WO2002100442A2 (en) * 2001-06-10 2002-12-19 Noxxon Pharma Ag Use of l-polynucleotides and derivatives thereof for in vivo imaging
WO2004030660A2 (en) * 2002-10-02 2004-04-15 The University Of British Columbia Compositions for treatment of prostate and other cancers
WO2008087641A2 (en) * 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
WO2010088899A2 (de) * 2009-02-06 2010-08-12 Freie Universität Berlin Pharmazeutische zusammensetzung zur behandlung von nebenwirkungen durch gabe von spiegelmeren

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHNATHAN C LAI ET AL: "Comparison of D-G3139 and Its Enantiomer L-G3139 in Melanoma Cells Demonstrates Minimal In Vitro but Dramatic In Vivo Chiral Dependency", MOLECULAR THERAPY, vol. 15, no. 2, 1 February 2007 (2007-02-01), pages 270 - 278, XP055033723, ISSN: 1525-0016, DOI: 10.1038/sj.mt.6300037 *
RAPHAËL BOISGARD ET AL: "In vivo biodistribution and pharmacokinetics of 18F-labelled Spiegelmers: a new class of oligonucleotidic radiopharmaceuticals", EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, BERLIN, DE, vol. 32, no. 4, 1 April 2005 (2005-04-01), pages 470 - 477, XP019332832, ISSN: 1619-7089, DOI: 10.1007/S00259-004-1669-8 *
W. G. PURSCHKE: "A DNA Spiegelmer to staphylococcal enterotoxin B", NUCLEIC ACIDS RESEARCH, vol. 31, no. 12, 15 June 2003 (2003-06-15), pages 3027 - 3032, XP055030769, DOI: 10.1093/nar/gkg413 *

Also Published As

Publication number Publication date
AU2012203994A1 (en) 2013-08-22
JP2014504589A (ja) 2014-02-24
KR20140043052A (ko) 2014-04-08
MX2013007543A (es) 2014-04-30
CN103492571A (zh) 2014-01-01
US20130345290A1 (en) 2013-12-26
WO2012089207A2 (de) 2012-07-05
BR112013017001A2 (pt) 2016-09-20
RU2013135647A (ru) 2015-02-10
CA2850863A1 (en) 2012-05-07
DE102010056610A1 (de) 2012-07-05
EP2668275A2 (de) 2013-12-04

Similar Documents

Publication Publication Date Title
WO2012078536A3 (en) Double stranded oligonucleotide compounds comprising threose modifications
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2009014887A3 (en) Stabilized immune modulatory rna (simra) compounds
WO2007117686A3 (en) Stabilized immune modulatory rna (simra) compounds for tlr7 and tlr8
WO2014066915A3 (en) Methods and compositions to produce ss-rnai activity with enhanced potency
WO2013074974A3 (en) Modified rnai agents
WO2010041913A3 (ko) Grs 단백질 또는 이의 단편의 신규한 용도
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
WO2008043753A3 (en) Rna antagonist compounds for the modulation of pcsk9
WO2008132234A3 (en) Rna antagonist compounds for the modulation of beta-catenin
MX2015005328A (es) Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas.
MX2012002502A (es) Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos.
WO2011038160A3 (en) Compositions and methods for silencing genes expressed in cancer
MX2014007233A (es) Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2009105774A3 (en) Amino acid inhibitors of cytochrome p450
EP2274442A4 (de) Konsensussequenzen von chikungunya-virusproteinen, dafür codierende nukleinsäuremoleküle und zusammensetzungen und verfahren zur verwendung davon
WO2013096958A8 (en) Compositions and methods for the delivery of biologically active rnas
WO2014060848A3 (en) Treatment methods using adenovirus
WO2011038933A3 (en) Anti-hsv antibody
WO2009071082A3 (en) Rna antagonist compounds for the modulation of pik3ca expression
WO2009051659A3 (en) Therapeutic sirna molecules for reducing vegfr1 expression in vitro and in vivo
WO2012138708A8 (en) Mhc engagement and clip modulation for the treatment of disease
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer
WO2012089207A3 (de) Pharmazeutische zusammensetzung enthaltend l-dna

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/007543

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2013546589

Country of ref document: JP

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012716194

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2012716194

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20137020401

Country of ref document: KR

Kind code of ref document: A

Ref document number: 2013135647

Country of ref document: RU

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2012203994

Country of ref document: AU

Date of ref document: 20120102

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13977088

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013017001

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2850863

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 112013017001

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130701